Study Summary
This trial is testing new drugs for breast cancer and trying to find which early indicators predict success for different types of tumors.
Eligible Conditions
- Breast Cancer
- Locally Advanced Breast Cancer
- HER2-negative Breast Cancer
- Hemangiosarcoma
- Hormone Receptor Positive Tumor
- HER2-positive Breast Cancer
- Hormone Receptor Negative Tumor
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: Three- and Five-Year Post-surgery Follow-up
Blood and Tissue Collection: Baseline, Post-Randomization, Pre-AC, Pre- and Post-Surgery
Establishing predictive and prognostic indices based on qualification and exploratory markers to predict pCR and residual cancer burden (RCB).
Four time points during the on-study phase: Baseline, Post-randomization, Pre-AC treatment and Pre-Surgery
MRI Volume
Post surgery based on upto 36-week treatment
Determine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry.
Post-Randomization, Pre-AC, Pre-Surgery, Post-Surgery upto One Year during follow-up
To determine incidence of adverse events (AEs), serious adverse events (SAEs), and laboratory abnormalities of each investigational agent tested.
Three- and Five-Year Post-surgery Follow-up
To determine three- and five-year relapse-free survival (RFS) and OS among the treatment arms.
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Trial Design
32 Treatment Groups
Standard Therapy
1 of 32
Pertuzumab and Trastuzumab
1 of 32
Zanidatamab in Block A and followed by SOC in block B
1 of 32
Endocrine Optimization Pilot: Lasofoxifene
1 of 32
ARX788 + Cemiplimab in Block A and followed by SOC in Block B
1 of 32
Endocrine Optimization Pilot: (Z)-Endoxifen
1 of 32
Ganetespib
1 of 32
Cemiplimab plus REGN3767
1 of 32
ARX788 in Block A and followed by SOC in Block B
1 of 32
Datopotamab Deruxtecan + Durvalumab in Block A and followed by SOC in block B
1 of 32
Trilaciclib with or without trastuzumab + pertuzumab
1 of 32
SYD985 ([vic-]trastuzumab duocarmazine)
1 of 32
Datopotamab Deruxtecan in Block A and followed by SOC in block B
1 of 32
VSV-IFNβ-NIS (VOYAGER V1™; VV1) + Cemiplimab in Block A and followed by SOC in b...
1 of 32
Endocrine Optimization Pilot: Amcenestrant + Letrozole
1 of 32
T-DM1 and Pertuzumab
1 of 32
MK-2206 with or without Trastuzumab
1 of 32
AMG 386 with or without Trastuzumab
1 of 32
SGN-LIV1A
1 of 32
Endocrine Optimization Pilot: Amcenestrant + Abemaciclib
1 of 32
Pembrolizumab 8 cycle
1 of 32
Durvalumab plus Olaparib
1 of 32
Patritumab with or without Trastuzumab
1 of 32
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or witho...
1 of 32
Pembrolizumab 4 cycle
1 of 32
Endocrine Optimization Pilot: Amcenestrant Monotherapy
1 of 32
Cemiplimab
1 of 32
Talazoparib plus Irinotecan
1 of 32
PLX3397
1 of 32
SD-101 + Pembrolizumab
1 of 32
Tucatinib
1 of 32
Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab
1 of 32
Active Control
Experimental Treatment
5000 Total Participants · 32 Treatment Groups
Primary Treatment: Trilaciclib with or without trastuzumab + pertuzumab · No Placebo Group · Phase 2
Zanidatamab in Block A and followed by SOC in block B
Drug
Experimental Group · 1 Intervention: Zanidatamab · Intervention Types: DrugEndocrine Optimization Pilot: Lasofoxifene
Drug
Experimental Group · 1 Intervention: Lasofoxifene · Intervention Types: DrugARX788 + Cemiplimab in Block A and followed by SOC in Block B
Drug
Experimental Group · 1 Intervention: ARX788 + Cemiplimab · Intervention Types: DrugEndocrine Optimization Pilot: (Z)-Endoxifen
Drug
Experimental Group · 1 Intervention: Z-endoxifen · Intervention Types: DrugGanetespib
Drug
Experimental Group · 1 Intervention: Ganetespib · Intervention Types: DrugCemiplimab plus REGN3767
Drug
Experimental Group · 1 Intervention: Cemiplimab plus REGN3767 · Intervention Types: DrugARX788 in Block A and followed by SOC in Block B
Drug
Experimental Group · 1 Intervention: ARX788 · Intervention Types: DrugDatopotamab Deruxtecan + Durvalumab in Block A and followed by SOC in block B
Drug
Experimental Group · 1 Intervention: Datopotamab deruxtecan + Durvalumab · Intervention Types: DrugTrilaciclib with or without trastuzumab + pertuzumab
Drug
Experimental Group · 1 Intervention: Trilaciclib with or without trastuzumab + pertuzumab · Intervention Types: DrugSYD985 ([vic-]trastuzumab duocarmazine)
Drug
Experimental Group · 1 Intervention: SYD985 ([vic-]trastuzumab duocarmazine) · Intervention Types: DrugDatopotamab Deruxtecan in Block A and followed by SOC in block B
Drug
Experimental Group · 1 Intervention: Datopotamab deruxtecan · Intervention Types: DrugVSV-IFNβ-NIS (VOYAGER V1™; VV1) + Cemiplimab in Block A and followed by SOC in block B
Drug
Experimental Group · 1 Intervention: VV1 + Cemiplimab · Intervention Types: DrugEndocrine Optimization Pilot: Amcenestrant + Letrozole
Drug
Experimental Group · 1 Intervention: Amcenestrant + Letrozole · Intervention Types: DrugT-DM1 and Pertuzumab
Drug
Experimental Group · 1 Intervention: T-DM1 and Pertuzumab · Intervention Types: DrugMK-2206 with or without Trastuzumab
Drug
Experimental Group · 1 Intervention: MK-2206 with or without Trastuzumab · Intervention Types: DrugAMG 386 with or without TrastuzumabExperimental Group · 2 Interventions: AMG 386 with or without Trastuzumab, AMG 386 and Trastuzumab · Intervention Types: Drug, Drug
SGN-LIV1A
Drug
Experimental Group · 1 Intervention: SGN-LIV1A · Intervention Types: DrugEndocrine Optimization Pilot: Amcenestrant + Abemaciclib
Drug
Experimental Group · 1 Intervention: Amcenestrant + Abemaciclib · Intervention Types: DrugPembrolizumab 8 cycle
Drug
Experimental Group · 1 Intervention: Pembrolizumab - 8 cycle · Intervention Types: DrugDurvalumab plus Olaparib
Drug
Experimental Group · 1 Intervention: Durvalumab plus Olaparib · Intervention Types: DrugPatritumab with or without Trastuzumab
Drug
Experimental Group · 1 Intervention: Patritumab and Trastuzumab · Intervention Types: DrugOral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab
Drug
Experimental Group · 1 Intervention: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab · Intervention Types: DrugPembrolizumab 4 cycle
Drug
Experimental Group · 1 Intervention: Pembrolizumab - 4 cycle · Intervention Types: DrugEndocrine Optimization Pilot: Amcenestrant Monotherapy
Drug
Experimental Group · 1 Intervention: Amcenestrant · Intervention Types: DrugCemiplimab
Drug
Experimental Group · 1 Intervention: Cemiplimab · Intervention Types: DrugTalazoparib plus Irinotecan
Drug
Experimental Group · 1 Intervention: Talazoparib plus Irinotecan · Intervention Types: DrugPLX3397
Drug
Experimental Group · 1 Intervention: PLX3397 · Intervention Types: DrugSD-101 + Pembrolizumab
Drug
Experimental Group · 1 Intervention: SD-101 + Pembrolizumab · Intervention Types: DrugTucatinib
Drug
Experimental Group · 1 Intervention: Tucatinib plus trastuzumab and pertuzumab · Intervention Types: DrugOral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab
Drug
Experimental Group · 1 Intervention: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab · Intervention Types: DrugStandard Therapy
Drug
ActiveComparator Group · 1 Intervention: Standard Therapy · Intervention Types: DrugPertuzumab and Trastuzumab
Drug
ActiveComparator Group · 1 Intervention: Pertuzumab and Trastuzumab · Intervention Types: DrugTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lasofoxifene
2004
Completed Phase 2
~550
Pexidartinib
FDA approved
Cemiplimab
FDA approved
Ganetespib
Not yet FDA approved
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: three- and five-year post-surgery follow-up
Who is running the clinical trial?
QuantumLeap Healthcare CollaborativeLead Sponsor
3 Previous Clinical Trials
1,523 Total Patients Enrolled
Laura Esserman, MD, MBAPrincipal InvestigatorUniversity of California, San Francisco
2 Previous Clinical Trials
100,017 Total Patients Enrolled
2 Trials studying Breast Cancer
100,017 Patients Enrolled for Breast Cancer
Eligibility Criteria
Age 18+ · All Participants · 16 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:References
- Barker, AD, CC Sigman, GJ Kelloff, NM Hylton, DA Berry, and LJ Esserman. 2009. “I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy”. Clinical Pharmacology & Therapeutics. Springer Science and Business Media LLC. doi:10.1038/clpt.2009.68.
- Esserman, Laura J., and Janet Woodcock. 2011. “Accelerating Identification and Regulatory Approval of Investigational Cancer Drugs”. Jama. American Medical Association (AMA). doi:10.1001/jama.2011.1837.
- Esserman, Laura J., Donald A. Berry, Angela DeMichele, Lisa Carey, Sarah E. Davis, Meredith Buxton, Cliff Hudis, et al.. 2012. “Pathologic Complete Response Predicts Recurrence-free Survival More Effectively by Cancer Subset: Results from the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657”. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO). doi:10.1200/jco.2011.39.2779.
- Hylton, Nola M., Jeffrey D. Blume, Wanda K. Bernreuter, Etta D. Pisano, Mark A. Rosen, Elizabeth A. Morris, Paul T. Weatherall, et al.. 2012. “Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—results from ACRIN 6657/I-SPY TRIAL”. Radiology. Radiological Society of North America (RSNA). doi:10.1148/radiol.12110748.
- Lin, Cheryl, I-SPY TRIAL Investigators, Meredith Becker Buxton, Dan Moore, Helen Krontiras, Lisa Carey, Angela DeMichele, et al.. 2011. “Locally Advanced Breast Cancers Are More Likely to Present as Interval Cancers: Results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, Interspore Trial)”. Breast Cancer Research and Treatment. Springer Science and Business Media LLC. doi:10.1007/s10549-011-1670-4.
- Esserman, Laura J., The I-SPY 1 TRIAL Investigators, Donald A. Berry, Maggie C. U. Cheang, Christina Yau, Charles M. Perou, Lisa Carey, et al.. 2011. “Chemotherapy Response and Recurrence-free Survival in Neoadjuvant Breast Cancer Depends on Biomarker Profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)”. Breast Cancer Research and Treatment. Springer Science and Business Media LLC. doi:10.1007/s10549-011-1895-2.
- I-SPY2 Trial Consortium, Douglas Yee, Angela M. DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans, Kathy S. Albain, et al.. 2020. “Association of Event-free and Distant Recurrence–free Survival with Individual-level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer”. JAMA Oncology. American Medical Association (AMA). doi:10.1001/jamaoncol.2020.2535.
- Pérez-García, José, Jesús Soberino, Fabricio Racca, María Gion, Agostina Stradella, and Javier Cortés. 2020. “Atezolizumab in the Treatment of Metastatic Triple-negative Breast Cancer”. Expert Opinion on Biological Therapy. Informa UK Limited. doi:10.1080/14712598.2020.1769063.
- Nanda, Rita, Minetta C. Liu, Christina Yau, Rebecca Shatsky, Lajos Pusztai, Anne Wallace, A. Jo Chien, et al.. 2020. “Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-stage Breast Cancer”. JAMA Oncology. American Medical Association (AMA). doi:10.1001/jamaoncol.2019.6650.
- Chien, A. Jo, Debasish Tripathy, Kathy S. Albain, W. Fraser Symmans, Hope S. Rugo, Michelle E. Melisko, Anne M. Wallace, et al.. 2020. “MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients with Human Epidermal Growth Factor Receptor 2–positive And/or Hormone Receptor–negative Breast Cancers in the I-SPY 2 Trial”. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO). doi:10.1200/jco.19.01027.
- Severson, Tesa M., Denise M. Wolf, Christina Yau, Justine Peeters, Diederik Wehkam, Philip C. Schouten, Suet-Feung Chin, et al.. 2017. “The Brca1ness Signature Is Associated Significantly with Response to PARP Inhibitor Treatment Versus Control in the I-SPY 2 Randomized Neoadjuvant Setting”. Breast Cancer Research. Springer Science and Business Media LLC. doi:10.1186/s13058-017-0861-2.
- Rugo, Hope S., Olufunmilayo I. Olopade, Angela DeMichele, Christina Yau, Laura J. van ’t Veer, Meredith B. Buxton, Michael Hogarth, et al.. 2016. “Adaptive Randomization of Veliparib–carboplatin Treatment in Breast Cancer”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa1513749.
- Park, John W., Minetta C. Liu, Douglas Yee, Christina Yau, Laura J. van ’t Veer, W. Fraser Symmans, Melissa Paoloni, et al.. 2016. “Adaptive Randomization of Neratinib in Early Breast Cancer”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa1513750.
- Symmans, W. Fraser, Christina Yau, Yunn-Yi Chen, Ron Balassanian, Molly E. Klein, Lajos Pusztai, Rita Nanda, et al.. 2021. “Assessment of Residual Cancer Burden and Event-free Survival in Neoadjuvant Treatment for High-risk Breast Cancer”. JAMA Oncology. American Medical Association (AMA). doi:10.1001/jamaoncol.2021.3690.
- Engebraaten, Olav, Christina Yau, Kristian Berg, Elin Borgen, Øystein Garred, Maria E. B. Berstad, Ane S. V. Fremstedal, et al.. 2021. “RAB5A Expression Is a Predictive Biomarker for Trastuzumab Emtansine in Breast Cancer”. Nature Communications. Springer Science and Business Media LLC. doi:10.1038/s41467-021-26018-z.
- Symmans, W. Fraser, Christina Yau, Yunn-Yi Chen, Ron Balassanian, Molly E. Klein, Lajos Pusztai, Rita Nanda, et al.. 2021. “Assessment of Residual Cancer Burden and Event-free Survival in Neoadjuvant Treatment for High-risk Breast Cancer”. JAMA Oncology. American Medical Association (AMA). doi:10.1001/jamaoncol.2021.3690.
- Wolf, Denise M., Christina Yau, Julia Wulfkuhle, Lamorna Brown-Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee, Zelos Zhu, et al.. 2022. “Redefining Breast Cancer Subtypes to Guide Treatment Prioritization and Maximize Response: Predictive Biomarkers Across 10 Cancer Therapies”. Cancer Cell. Elsevier BV. doi:10.1016/j.ccell.2022.05.005.
- Osdoit, Marie, Christina Yau, W. Fraser Symmans, Judy C. Boughey, Cheryl A. Ewing, Ron Balassanian, Yunn-Yi Chen, et al.. 2022. “Association of Residual Ductal Carcinoma in Situ with Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial”. JAMA Surgery. American Medical Association (AMA). doi:10.1001/jamasurg.2022.4118.
- Trapani D, Ferraro E, Giugliano F, Boscolo Bielo L, Curigliano G, Burstein HJ. Postneoadjuvant treatment for triple-negative breast cancer. Curr Opin Oncol. 2022 Nov 1;34(6):623-634. doi: 10.1097/CCO.0000000000000893. Epub 2022 Aug 19. Review.
- Osdoit M, Yau C, Symmans WF, Boughey JC, Ewing CA, Balassanian R, Chen YY, Krings G, Wallace AM, Zare S, Fadare O, Lancaster R, Wei S, Godellas CV, Tang P, Tuttle TM, Klein M, Sahoo S, Hieken TJ, Carter JM, Chen B, Ahrendt G, Tchou J, Feldman M, Tousimis E, Zeck J, Jaskowiak N, Sattar H, Naik AM, Lee MC, Rosa M, Khazai L, Rendi MH, Lang JE, Lu J, Tawfik O, Asare SM, Esserman LJ, Mukhtar RA. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. JAMA Surg. 2022 Nov 1;157(11):1034-1041. doi: 10.1001/jamasurg.2022.4118.
- Esserman LJ, Woodcock J. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA. 2011 Dec 21;306(23):2608-9. doi: 10.1001/jama.2011.1837. No abstract available.
- Perez-Garcia J, Soberino J, Racca F, Gion M, Stradella A, Cortes J. Atezolizumab in the treatment of metastatic triple-negative breast cancer. Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25.
- Trapani D, Ferraro E, Giugliano F, Boscolo Bielo L, Curigliano G, Burstein HJ. Postneoadjuvant treatment for triple-negative breast cancer. Curr Opin Oncol. 2022 Nov 1;34(6):623-634. doi: 10.1097/CCO.0000000000000893. Epub 2022 Aug 19.
- Engebraaten O, Yau C, Berg K, Borgen E, Garred O, Berstad MEB, Fremstedal ASV, DeMichele A, Veer LV', Esserman L, Weyergang A. RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer. Nat Commun. 2021 Nov 5;12(1):6427. doi: 10.1038/s41467-021-26018-z.
- Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppe JP, Lu R, Braun J; I-SPY2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022 Jun 13;40(6):609-623.e6. doi: 10.1016/j.ccell.2022.05.005. Epub 2022 May 26.
- Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppe JP, Lu R, Braun J; I-SPY2 Investigators; Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022 Jun 13;40(6):609-623.e6. doi: 10.1016/j.ccell.2022.05.005. Epub 2022 May 26.
- I-SPY2 Trial Consortium; Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1355-1362. doi: 10.1001/jamaoncol.2020.2535.
- 2010. "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01042379.
Frequently Asked Questions
What health issues does the combination of Trilaciclib, trastuzumab and pertuzumab aim to address?
"Trilaciclib is a potential therapy for anovulatory cycles, melanoma, and metastatic neoplasms combined with or without trastuzumab + pertuzumab." - Anonymous Online Contributor
Unverified Answer
Is this research endeavor accepting new participants?
"Affirmative. Clinicaltrials.gov details that this clinical trial, which first went live on March 1st 2010, is presently seeking volunteers. The study requires 5000 recruits to be found at 28 different medical sites." - Anonymous Online Contributor
Unverified Answer
Have researchers investigated the effect of combining Trilaciclib with trastuzumab and pertuzumab in other studies?
"Currently, 642 trials for Trilaciclib with or without trastuzumab + pertuzumab are in their third phase of clinical testing. Furthermore, these tests can be found at 136713 different sites worldwide with a noteworthy concentration located within Seattle, Washington." - Anonymous Online Contributor
Unverified Answer
How many individuals are allowed to take part in this medical experiment?
"Correct. The information on clinicaltrials.gov affirms that this medical trial, which was first listed on March 1st 2010, is currently recruiting patients. 5000 participants need to be enrolled from 28 different locations." - Anonymous Online Contributor
Unverified Answer
How widespread is the implementation of this clinical investigation?
"Herbert-Herman Cancer Center, Sparrow Hospital in Lansing, Michigan, HOAG Memorial Hospital Presbyterian in Newport Beach, New York and University of Rochester Wilmot Cancer Institute in Rochester, New Jersey are among the 28 sites that are recruiting for this trial." - Anonymous Online Contributor
Unverified Answer
How have the interactions between Trilaciclib, trastuzumab and pertuzumab been assessed for safety?
"Due to its Phase 2 status, meaning there is some data available in regards to safety but none for efficacy, Trilaciclib with or without trastuzumab + pertuzumab has been assigned a score of 2." - Anonymous Online Contributor
Unverified Answer